- Pfizer Inc.
- Serenex Inc.
- Biogen Inc.
- MedImmune LLC
- AstraZeneca PLC
- Infinity Pharmaceuticals Inc.
- Kosan Biosciences Inc.
- Takeda Oncology
- Synta Pharmaceuticals Corp.
- Duke University
- GlaxoSmithKline PLC
- Johnson & Johnson
- Novartis AG
- Vernalis PLC
- National Institutes of Health
- National Cancer Institute
- Mucosal Therapeutics LLC
- Pfizer buys Serenex, gaining its Hsp90 program
- Biogen Idec buys Conforma for $150mm plus earn-outs
- AstraZeneca buys MedImmune for $15.6bn
- Infinity, MedImmune, AZ restructure Hedgehog deal
- Novartis and Vernalis in cancer deal; alliance ends
- Pfizer licenses Kosan's motilin agonists
- Serenex gets a Phase II candidate from Mucosal Therapeutics
- Discovery Partners and Infinity merge
- Pharmion buys Cabrellis for $59mm plus earn-outs
- J&J acquires OraPharma for $7.41/share
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. email@example.com.
All fields are required.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.